(PharmaNewsWire.Com, November 30, 2017 ) According to the report Generic Drugs, published by Market Data Forecast, the North America market is projected to reach USD 202.5 billion by 2022, at a CAGR of 9.81% from 2017 to 2022.
Generic drugs can be described as pharmaceutical drugs that have exactly the same dosage, side effects, intended use, risks, safety, effects and strength as the genuine drug, for example metformin. They are price effective as compared to branded drugs. Generic drugs are also called as abbreviated drugs. In order to sell a generic drug, manufacturing company has to submit an AND (Abbreviated New Drug) application for getting it approved. Get a comprehensive overview of the North America Generic Drugs: http://www.marketdataforecast.com/market-reports/north-america-generic-drugs-market-2184/
North America Generic Drugs: Drivers & Restraints The key driving force of North America Generic Drugs market is the patent expiry of branded drugs. Another trend which is expected to drive this market is the rising incidence of outsourcing. Currently, a lot of doctors in the United States are prescribing generic drugs which is expected to increase even more. Vendors are utilizing outsourcing as a plan in order to decrease their capital that will be an advantage to generic drugs. The key constraint to this market is rigid rules which are setup by FDA for getting drugs approval as well as the threat of counterfeit drugs. Get accurate market forecast and analysis on the North America Generic Drugs. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/north-america-generic-drugs-market-2184/request-sample
North America Generic Drugs: Segmentation By Type • Introduction • Biosimilars • Simple generics • Super generics By Therapeutic drugs • Introduction • Cardiovascular Products • Anti-infective Drugs • Anti Arthritis Drugs • Central Nervous System Drugs • Anti Cancer Drugs • Respiratory System Drugs • Others By Geography • North America o United States o Canada
North America Generic Drugs: Overview Factors like growing incidence of outsourcing and patent expiry of branded drugs are affecting the growth of this market positively. However, other factors such as rigid rules which are set up by the Food and Drug Administration in getting new drugs approved and threat from counterfeit drugs are restraining the growth of this market. In this market, biosimilar drugs are expected to grow at the fastest rate. Globally, North America region has the largest market for generic drugs in the world by share. In the North America region, United States has the largest share. North America Generic Drugs: Key Players Some of the major companies dominating North America Generic Drugs Market are Mylan, Inc., Industries, Ltd., Ltd, Apotex, Inc., Watson Pharmaceuticals, Ltd., Actavis, Par Pharmaceutical, Inc., Dr. Reddy’s Laboratories, Ranbaxy Laboratories, Sandoz International GmbH, Hospira, Inc., Teva Pharmaceutical among others.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: